Absci Corporation, a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company recorded a revenue of $0.6 million for the quarter ended June 30, 2025, a decrease from $1.3 million in the same period the previous year. The net loss for the quarter was $30.6 million, compared to a net loss of $24.8 million in the second quarter of 2024. Research and development expenses increased to $20.5 million from $15.3 million, attributed to the advancement of Absci's internal programs and related costs. Selling, general, and administrative expenses decreased to $8.5 million from $9.3 million due to a reduction in stock compensation expense. Significantly, Absci strengthened its financial position by raising approximately $64 million in July 2025 through a public offering and the use of its at-the-market facility. As a result, the company anticipates that its cash, cash equivalents, and short-term investments, which stood at $117.5 million as of June 30, 2025, will be sufficient to fund operations into the first half of 2028. In addition to its financial results, Absci announced an expanded collaboration with Almirall, with a new focus on a second target for dermatological indications.